Clinical-pharmacological strategies to assess drug interaction potential during drug development.

Abstract:

:Drug interactions in patients receiving multiple drug regimens are a constant concern for the clinician. With the increased availability of new drugs and their concomitant use with other drugs, there has been a rise in the potential for adverse drug interactions as demonstrated by the recent withdrawals of newly marketed drugs because of unacceptable interaction profiles. Therefore, the interaction potential of a new compound has to be assessed in detail, starting with preclinical in vitro and in vivo studies at candidate selection and continuously followed up through preclinical and clinical development. Since formal in vivo studies of all possible drug interactions are neither practicable nor suggestive, a careful selection of a limited number of drug combinations to be investigated in vivo during the development phase is indicated. Based on knowledge of pharmacokinetic and biopharmaceutical properties, a well balanced link between in vitro investigations and carefully selected in vivo interaction studies allows full assessment of the potential of a new drug to cause clinically relevant pharmacokinetic drug-drug interactions, prediction of a lack of interactions and derivation of the proper dose recommendations. Clinical pharmacology plays a number of key roles within the process of collecting information on drug interactions during preclinical and clinical development: addressing issues and/or favourable properties to be expected, thus contributing to the scientific assessment of development potential; setting up a rational in vivo drug-drug interaction programme; performing early mechanistic studies to link in vitro with in vivo information (employing 'cocktail' approaches if possible); reviewing co-medication sections for clinical trials; and conducting labelling-oriented interaction studies, after proof of concept. The fact that interactions can occur between various active substances should by itself be a conclusive argument against unnecessary polypharmacy. Prescribing fewer drugs on a rational basis can reduce the risk of adverse effects secondary to drug interactions and may help to improve the quality of drug treatment and to save costs.

journal_name

Drug Saf

journal_title

Drug safety

authors

Kuhlmann J,Mück W

doi

10.2165/00002018-200124100-00001

keywords:

subject

Has Abstract

pub_date

2001-01-01 00:00:00

pages

715-25

issue

10

eissn

0114-5916

issn

1179-1942

journal_volume

24

pub_type

杂志文章,评审
  • Enabling Data-Driven Clinical Quality Assurance: Predicting Adverse Event Reporting in Clinical Trials Using Machine Learning.

    abstract:INTRODUCTION:Adverse event (AE) under-reporting has been a recurrent issue raised during health authorities Good Clinical Practices (GCP) inspections and audits. Moreover, safety under-reporting poses a risk to patient safety and data integrity. The current clinical Quality Assurance (QA) practices used to detect AE un...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-019-00831-4

    authors: Ménard T,Barmaz Y,Koneswarakantha B,Bowling R,Popko L

    更新日期:2019-09-01 00:00:00

  • Current challenges and controversies in drug-induced liver injury.

    abstract::Current key challenges and controversies encountered in the identification of potentially hepatotoxic drugs and the assessment of drug-induced liver injury (DILI) are covered in this article. There is substantial debate over the classification of DILI itself, including the definition and validity of terms such as 'int...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/BF03261997

    authors: Corsini A,Ganey P,Ju C,Kaplowitz N,Pessayre D,Roth R,Watkins PB,Albassam M,Liu B,Stancic S,Suter L,Bortolini M

    更新日期:2012-12-01 00:00:00

  • Reversal Strategies for NOACs: State of Development, Possible Clinical Applications and Future Perspectives.

    abstract::The non-vitamin K antagonist oral anticoagulants (NOACs) are used for thromboembolic prophylaxis of patients with atrial fibrillation and in the treatment as well as secondary prophylaxis of patients with venous thromboembolism. Even though NOACs have a better safety profile than vitamin K antagonists (VKAs), there wi...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-015-0357-x

    authors: Husted S,Verheugt FW,Comuth WJ

    更新日期:2016-01-01 00:00:00

  • Risk-benefit assessment of drugs used in the treatment of inflammatory bowel disease.

    abstract::Although the aetiology of inflammatory bowel disease remains elusive, many agents are available for the control of symptoms and inflammation. Knowledge of drug pharmacology, indications and side effects is essential to ensure the best possible clinical care while minimising toxicity and inappropriate use. Sulfasalazin...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199106030-00005

    authors: Hanauer SB,Stathopoulos G

    更新日期:1991-05-01 00:00:00

  • Risk management and outcomes of adverse events to pioglitazone in primary care in the UK: an observational study.

    abstract:BACKGROUND:Pioglitazone is an antidiabetic drug that belongs to the thiazolidinedione (TZD) class of insulin-sensitizing agents. Adverse events to pioglitazone of potential severity are listed in the 'special warnings and special precautions for use' section of the pioglitazone summary of product characteristics (SPC),...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200932030-00005

    authors: Fogg C,Kasliwal R,Shakir SA

    更新日期:2009-01-01 00:00:00

  • Neuropsychiatric reactions to nonsteroidal anti-inflammatory drugs (NSAIDs). The New Zealand experience.

    abstract::The New Zealand Medicines Adverse Reactions Committee has been monitoring reports of adverse drug reactions (ADRs) since 1965. We wished to determine the numbers of voluntary reports of different types of ADR to all nonsteroidal anti-inflammatory drugs (NSAIDs) over a long time period and relate these to age. As the e...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-199207060-00006

    authors: Clark DW,Ghose K

    更新日期:1992-11-01 00:00:00

  • Correction to: Drug-Induced Dental Caries: A Disproportionality Analysis Using Data from VigiBase.

    abstract::Dental caries is defined as a pathological breakdown of the tooth. It is an infectious phenomenon involving a multifactorial aetiology. The impact of drugs on cariogenic risk has been poorly investigated. ...

    journal_title:Drug safety

    pub_type: 杂志文章,已发布勘误

    doi:10.1007/s40264-018-0672-0

    authors: Patras de Campaigno E,Kebir I,Montastruc JL,Rueter M,Maret D,Lapeyre-Mestre M,Sallerin B,Despas F

    更新日期:2018-08-01 00:00:00

  • Coronary Risks Associated with Diclofenac and Other NSAIDs: An Update.

    abstract::The risk of coronary events with non-steroidal anti-inflammatory drugs has been the subject of much debate since the original trial of rofecoxib raised the issue. Since then, over almost 20 years, such risks have been shown in clinical trials of long-term high-dose users, and in observational studies comparing users w...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-019-00900-8

    authors: Moore N

    更新日期:2020-04-01 00:00:00

  • Principles of signal detection in pharmacovigilance.

    abstract::Adverse drug effects are manifold and heterogenous. Many situations may hamper the signalling (i.e. the detection of early warning signs) of adverse effects and new signals often differ from previous experiences. Signals have qualitative and quantitative aspects. Different categories of adverse effects need different ...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199716060-00002

    authors: Meyboom RH,Egberts AC,Edwards IR,Hekster YA,de Koning FH,Gribnau FW

    更新日期:1997-06-01 00:00:00

  • Ethical and Practical Considerations in Removing Black Box Warnings from Drug Labels.

    abstract::Boxed warnings-also known as "black box" warnings-can be a powerful tool in communicating drug risks to physicians and patients. The overall number of boxed warnings has grown in recent years as the US Food and Drug Administration (FDA) has approved more drugs on the basis of limited pre-marketing information and as n...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-016-0419-8

    authors: Yeh JS,Sarpatwari A,Kesselheim AS

    更新日期:2016-08-01 00:00:00

  • Fatal venous thromboembolism associated with different combined oral contraceptives: a study of incidences and potential biases in spontaneous reporting.

    abstract:BACKGROUND:Fatal venous thromboembolism (VTE) is a rare complication of combined oral contraceptive (COC) treatment. This study aims to determine incidences of fatal VTE in relation to the type of COC and the percentage of cases reported to the Swedish Adverse Drug Reactions Advisory Committee (SADRAC). A further aim i...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200528100-00007

    authors: Hedenmalm K,Samuelsson E

    更新日期:2005-01-01 00:00:00

  • Drug therapy and the older person: role of the pharmacist.

    abstract::Older people in the UK receive a disproportionate amount of medication. They comprise 18% of the population but receive 45% of all prescription items. Not surprisingly they experience drug-related illnesses - in 1980, 1 in 10 admissions to acute geriatric units were wholly or partly due to adverse drug reactions. Drug...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199819040-00001

    authors: Denham MJ,Barnett NL

    更新日期:1998-10-01 00:00:00

  • Antidepressants and the Risk of Hemorrhagic Stroke in the Elderly: a Nested Case-Control Study.

    abstract:BACKGROUND AND PURPOSE:Selective serotonin reuptake inhibitors (SSRIs) are frequently prescribed in the elderly due to a more favorable risk profile than other antidepressants (ADs). However, SSRIs are associated with an increased risk of gastrointestinal bleeding, while evidence on the risk of hemorrhagic stroke (HS) ...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-019-00837-y

    authors: Schäfer W,Princk C,Kollhorst B,Schink T

    更新日期:2019-09-01 00:00:00

  • Assessment of Self-Administration of Romiplostim in Patients with Immune Thrombocytopenic Purpura after Receipt of Home Administration Training Materials: a Cross-Sectional Study.

    abstract:INTRODUCTION:Romiplostim is a subcutaneously administered thrombopoietin-receptor agonist approved in the European Union for self-administration (or administration by a caregiver) in selected adult patients with chronic primary immune thrombocytopenia refractory to other treatments. To mitigate the risk of medication e...

    journal_title:Drug safety

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s40264-018-0723-6

    authors: Schipperus M,Kaiafa G,Taylor L,Wetten S,Kreuzbauer G,Boshier A,Seesaghur A

    更新日期:2019-01-01 00:00:00

  • The combined oral contraceptive. Risks and adverse effects in perspective.

    abstract::The risks and adverse effects of the low dose, new generation progestogen combined oral contraceptives (COCs) are much lower than original studies involving pills containing 50 micrograms estrogen. The main effects are those on the cardiovascular system, lipid and glucose metabolism and cancer. Any effect of the COC o...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199512020-00002

    authors: Bagshaw S

    更新日期:1995-02-01 00:00:00

  • Evidence of Misclassification of Drug-Event Associations Classified as Gold Standard 'Negative Controls' by the Observational Medical Outcomes Partnership (OMOP).

    abstract:INTRODUCTION:Pharmacovigilance includes analysis of large databases of information on drugs and events using algorithms that detect disproportional frequencies of associations. In order to test such algorithms, attempts have been made to provide canonical reference lists of so-called 'positive controls' and 'negative c...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-016-0392-2

    authors: Hauben M,Aronson JK,Ferner RE

    更新日期:2016-05-01 00:00:00

  • Post-approval safety issues with innovative drugs: a European cohort study.

    abstract:BACKGROUND:At time of approval, knowledge of the full benefit risk of any drug is limited, in particular with regards to safety. Post-approval surveillance of potential drug safety concerns is recognized as an important task of regulatory agencies. For innovative, often first-in-class drugs, safety knowledge at time of...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-013-0094-y

    authors: Mol PG,Arnardottir AH,Motola D,Vrijlandt PJ,Duijnhoven RG,Haaijer-Ruskamp FM,de Graeff PA,Denig P,Straus SM

    更新日期:2013-11-01 00:00:00

  • Allergic reactions to medicines derived from Pelargonium species.

    abstract::Pelargonium (Pelargonium sidoides DC and P. reniforme Curtis) is reported to have immune modulating properties and antibacterial activity, and Pelargonium extracts have been used for the treatment of respiratory tract and gastrointestinal infections. Introduced in the early 1980s in Germany, Umckaloabo (ISO Arzneimitt...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200730080-00004

    authors: de Boer HJ,Hagemann U,Bate J,Meyboom RH

    更新日期:2007-01-01 00:00:00

  • Drug-induced skin, nail and hair disorders.

    abstract::Drug eruptions are among the most common adverse drug reactions, affecting approximately 3% of hospitalised patients. Although the rate of severe cutaneous adverse reactions to medications is low, these reactions can affect anyone who takes medication, and can result in death or disability. Two general patterns can be...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200730110-00003

    authors: Valeyrie-Allanore L,Sassolas B,Roujeau JC

    更新日期:2007-01-01 00:00:00

  • Adverse effects of newer cephalosporins. An update.

    abstract::While classifications into generations according to antimicrobial activity has helped clinicians incorporate the increasing number of cephalosporins into their pharmacological repertoire, adverse effects among the different agents fail to follow similar categories. In general, cephalosporins are fairly well tolerated ...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199309020-00005

    authors: Thompson JW,Jacobs RF

    更新日期:1993-08-01 00:00:00

  • Betahistine: a retrospective synopsis of safety data.

    abstract::Betahistine is a structural analogue of histamine that is prescribed for the treatment of vestibular disorders such as Ménière's disease and the symptomatic treatment of vertigo. It is estimated from sales information that >130 million patients have been exposed to the drug since its registration in 1968. In this revi...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200629110-00004

    authors: Jeck-Thole S,Wagner W

    更新日期:2006-01-01 00:00:00

  • Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance.

    abstract:BACKGROUND:Hepatic dysfunction, manifested as liver enzyme elevations, occurs frequently in patients who are treated with interferon, however, data for patients with multiple sclerosis are limited. OBJECTIVE:To retrospectively assess the safety profile of interferon-beta-1a therapy with respect to liver function durin...

    journal_title:Drug safety

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00002018-200326110-00006

    authors: Francis GS,Grumser Y,Alteri E,Micaleff A,O'Brien F,Alsop J,Stam Moraga M,Kaplowitz N

    更新日期:2003-01-01 00:00:00

  • Nonsteroidal anti-inflammatory drugs and reversible female infertility: is there a link?

    abstract::Nonsteroidal anti-inflammatory drugs (NSAIDs) are frequently prescribed to women of child-bearing age. Three case series highlight the possibility of a link between NSAIDs and reversible infertility. The pharmacological target of NSAIDs is cyclo-oxygenase (COX), which catalyses the first rate-limiting step in the prod...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-200225080-00001

    authors: Stone S,Khamashta MA,Nelson-Piercy C

    更新日期:2002-01-01 00:00:00

  • Monitoring outcomes of pregnancy following drug exposure: a company-based pregnancy registry program.

    abstract::Women who discover they are pregnant after exposure to a drug and pregnant women who have a condition that requires continued treatment during pregnancy are told to balance the benefits and risks of the exposure to justify continuation of treatment, discontinuation of treatment or, possibly, pregnancy termination. How...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200427060-00001

    authors: Shields KE,Wiholm BE,Hostelley LS,Striano LF,Arena SR,Sharrar RG

    更新日期:2004-01-01 00:00:00

  • The impact of unlicensed and off-label drug use on adverse drug reactions in paediatric patients.

    abstract:BACKGROUND AND OBJECTIVE:Many drugs that are used to treat children are either not licensed for use in paediatric patients (unlicensed) or prescribed outside the terms of the product licence (off label). The incidence of adverse drug reactions (ADRs) associated with the use of such drugs is yet to be established. This ...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/00002018-200427130-00006

    authors: Neubert A,Dormann H,Weiss J,Egger T,Criegee-Rieck M,Rascher W,Brune K,Hinz B

    更新日期:2004-01-01 00:00:00

  • Authors' Response to Braillon's Comment on: "Limited Evidence for Risk Factors for Proarrhythmia and Sudden Cardiac Death in Patients Using Antidepressants: Dutch Consensus on ECG Monitoring".

    abstract:: ...

    journal_title:Drug safety

    pub_type: 评论,信件

    doi:10.1007/s40264-018-0716-5

    authors: Simoons M,Seldenrijk A,Mulder H,van Roon E,Bakker R,Ruhé H

    更新日期:2018-12-01 00:00:00

  • Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre.

    abstract:BACKGROUND:Rituximab is a monoclonal antibody approved for treating CD20-positive B-cell non-Hodgkin's lymphoma and rheumatoid arthritis but is used off-label for treating many autoimmune disorders, including multiple sclerosis (MS). Similarly to other monoclonal antibodies, the incidence of infusion-related reactions ...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.2165/11585960-000000000-00000

    authors: Brown BA,Torabi M

    更新日期:2011-02-01 00:00:00

  • Adverse effects and drug interactions of clinical importance with antiviral drugs.

    abstract::Most antiviral drugs are nucleoside analogues with potential teratogenic, embryotoxic, carcinogenic and antiproliferative activities. They must be administered with caution during pregnancy, because some are known teratogens (e.g. amantadine) and a similar propensity cannot be entirely excluded for others (e.g. aciclo...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.2165/00002018-199410040-00002

    authors: Morris DJ

    更新日期:1994-04-01 00:00:00

  • Benzodiazepine Use and Risk of Acute Angle-Closure Glaucoma: A Population-Based Case-Crossover Study.

    abstract:INTRODUCTION:Theoretically, benzodiazepines (BZDs) can narrow the iridocorneal angle and induce acute angle-closure glaucoma (AACG). However, little evidence exists regarding this association. OBJECTIVE:The objective of this study was to assess whether the use of BZDs is associated with the risk of AACG. METHODS:We c...

    journal_title:Drug safety

    pub_type: 杂志文章

    doi:10.1007/s40264-020-00914-7

    authors: Kim WJ,Li J,Oh IS,Song I,Lee E,Namkoong K,Shin JY

    更新日期:2020-06-01 00:00:00

  • Safety and Tolerability of Adoptive Cell Therapy in Cancer.

    abstract::Adoptive T cell therapy (ACT) is a safe and effective personalized cancer immunotherapy that can comprise naturally occurring ex vivo expanded cells (e.g., tumor-infiltrating lymphocytes [TIL]) or T cells genetically engineered to confer antigen specificity (T-cell receptor [TCR] or chimeric antigen receptor [CAR] eng...

    journal_title:Drug safety

    pub_type: 杂志文章,评审

    doi:10.1007/s40264-018-0779-3

    authors: Wolf B,Zimmermann S,Arber C,Irving M,Trueb L,Coukos G

    更新日期:2019-02-01 00:00:00